Tricida to Report Long-Term Clinical Trial Results for TRC101 in CKD Patients with Metabolic Acidosis and Host Conference Call and Webcast on Thursday, March 28, 2019

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA) today announced that it will report results
from its blinded, 40-week extension trial, TRCA-301E, tomorrow morning
at 7:15 am Eastern Time. Tricida will host a conference call and webcast
at 8:00 am Eastern Time to discuss the TRCA-301E clinical trial results
and its financial results and other business progress. The call or
webcast may be accessed as follows:

A replay of the webcast will be available on Tricida’s website
approximately two hours following the completion of the call and will be
available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and
commercialization of its drug candidate, TRC101, a non-absorbed,
orally-administered polymer designed to treat metabolic acidosis in
patients with chronic kidney disease (CKD). Metabolic acidosis is a
condition commonly caused by CKD that is believed to accelerate the
progression of kidney deterioration. It is estimated to pose a health
risk to approximately three million patients with CKD in the United
States. Tricida has successfully completed a Phase 3, double-blind,
placebo-controlled trial of TRC101 in patients with CKD and metabolic
acidosis. Tricida plans to submit a New Drug Application (NDA), in the
second half of 2019, seeking approval of TRC101 through the U.S. Food
and Drug Administration’s (FDA’s) Accelerated Approval Program.

For more information about Tricida, please visit www.Tricida.com.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements, including for
example, statements about our ability to submit an NDA for TRC101 under
the FDA’s Accelerated Approval Program. Forward‐looking statements
involve known and unknown risks, uncertainties, assumptions and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward‐looking
statements. These risks and uncertainties include, among others, the
timing of Tricida’s NDA submission; that many drug candidates that have
completed Phase 3 trials do not become approved drugs on a timely or
cost effective basis or at all; there can be no assurance that the FDA
would approve an NDA under the Accelerated Approval Program, or at all,
and even if approval for a drug is obtained, there can be no assurance
that it will be adopted in the market or accepted as a benefit to
patients and healthcare providers; possible safety and efficacy concerns
and that we completely rely on third-party suppliers to manufacture
TRC101. The forward-looking statements contained in this press release
reflect Tricida’s current views with respect to future events, and
Tricida does not undertake and specifically disclaims any obligation to
update any forward-looking statements.

Contacts

Jackie Cossmon, IRC
Tricida, Inc.
Vice President of Investor
Relations and Communications
[email protected]